Preparation method of composite injection for chemotherapy of colon cancer

Abstract

The invention provides a preparation method of composite injection for the chemotherapy of colon cancer, which comprises the steps of: respectively taking raw material blood plasma from a blood bank according to different blood types; centrifuging and adjusting density; extracting low-density lipoprotein; preparing carrier of targeted medicine by purifying the low-density lipoprotein; compositing with aclacinomycin targeted medicine for treating cancer; and injecting the composite low-density lipoprotein-aclacinomycin medicine into the human body with the same type as the raw material blood plasma to achieve the aim of treating the colon cancer. The clinical practice proves that the low-density lipoprotein-aclacinomycin composite injection can obtain satisfactory treatment effect on clinically treating the colon cancer, has no obvious chemotherapy toxic and side effects, has effective rate at 100% for treating 185 colon cancer patients, has 3 years survival rate at more than 96%, and has good popularization and use value.

Description

technical field [0001] The invention relates to a preparation method of a cancer chemotherapy preparation, in particular to a preparation method of a compound injection for chemotherapy of colon cancer. Background technique [0002] With the aggravation of environmental pollution and changes in diet structure, the incidence and mortality of colon cancer are increasing year by year, seriously endangering the health of the people. In the treatment plan of colon cancer, chemotherapy is still the main means in its comprehensive treatment measures. At present, the common deficiency of the chemotherapeutic drugs used in the chemotherapy of various tumors is that the anti-tumor chemotherapeutic drugs lack selectivity. While killing cancer cells, they also damage healthy cells, reduce the immune function of the human body, and cause many toxic effects. Side effects affect the clinical application of chemotherapy drugs. In order to improve the efficacy of anti-tumor drugs and reduce...

AI Technical Summary

Problems solved by technology

At present, the common deficiency of the chemotherapeutic drugs used in the chemotherapy of various tumors is that the anti-tumor chemotherapeutic drugs lack selectivity. While killing cancer cells, they also damage healthy cells, reduce the immune function of the human body, and cause many toxic effects. Side effects affect the clinical application of chemotherapy drugs. In order to improve the efficacy of anti-tumor drugs and reduce the damage and toxicity to normal cells, the medical community has tried many times to use antibodies, liposomes, hormones and other macromolecules as tumor chemotherapy drugs. Carriers, in order to increase the targeting of drugs, that is, "targeted therapy"

However, a major problem in the actual clinical application process is that the reticuloendothelial system of the liver and spleen removes these complexes in the blood as foreign harmful substances and quickly removes them from the blood stream, thereby reducing the impact of the drug-macromolecule complex on the bloodstream. The time of action of tumor cells affects the therapeutic effect of drugs